• Publications
  • Influence
Long-Term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD)
Very early or early onset of bipolar disorder might herald a more severe disease course in terms of chronicity and comorbidity and whether early intervention might modify this risk merits further investigation. Expand
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine isMore effective than olanZapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms. Expand
Oral topiramate for treatment of alcohol dependence: a randomised controlled trial
Topiramate (up to 300 mg per day) is more efficacious than placebo as an adjunct to standardised medication compliance management in treatment of alcohol dependence. Expand
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
The use of adjunctive, standard antidepressant medication, as compared with the use of mood stabilizers, was not associated with increased efficacy or with increased risk of treatment-emergent affective switch. Expand
Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD)
The methodology used for the selection and certification of the clinical treatment centers, training study personnel, the general approach to clinical management, and the sequential treatment strategies offered in the STEP-BD standard and randomized care pathways for bipolar depression and relapse prevention are reviewed. Expand
Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression.
Antidepressants may not be useful adjunctive therapy for bipolar depressed patients with high serum lithium levels or who have symptoms that are refractory to the antidepressant effects of lithium, but both paroxetine and imipramine were superior to placebo for patients with low serum lithium Levels. Expand
Efficacy of Divalproex vs Lithium and Placebo in the Treatment of Mania
Divalproex was as effective in rapid-cycling manic patients as in other patients and appears to be independent of prior responsiveness to lithium, while lithium was significantly more effective than placebo in reducing the symptoms of acute mania. Expand
A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
Both lamotrigine and lithium were superior to placebo for the prevention of relapse or recurrence of mood episodes in patients with bipolar I disorder who had recently experienced a manic or hypomanic episode. Expand
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania
  • H. Grunze, E. Vieta, +5 authors WFSBP Task Force on Treatment Guidelines for Bipol
  • Medicine
  • The world journal of biological psychiatry : the…
  • 1 January 2009
These updated guidelines are based on a first edition that was published in 2003, and have been edited and updated with the available scientific evidence until end of 2008. Their purpose is to supplyExpand
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Risperidone plus a mood stabilizer was more efficacious than a mood stabilizeizer alone, and as efficacious as haloperidol plus a Mood stabilizer, for the rapid control of manic symptoms and was well tolerated. Expand